Rubicon Research 在 2025 年 10 月 9 日以 137.7 亿卢比首次公开募股之前，从主要投资者那里筹集了 61.9 亿卢比。 Rubicon Research raises ₹619 crore from anchor investors ahead of its ₹1,377-crore IPO on October 9, 2025.

Rubaicon Research Limited在其于2025年10月9日开放订阅的IPO $1,377-crore IPO 之前,从32个主机投资者那里筹集到619克朗。 Rubicon Research Limited has raised ₹619 crore from 32 anchor investors ahead of its ₹1,377-crore IPO, which opens for subscription on October 9, 2025. IPO价格在每股461至485美元之间,包括新发行的500克朗和出售877.5克朗的报价。 The IPO, priced between ₹461 and ₹485 per share, includes a fresh issue of ₹500 crore and an Offer for Sale of ₹877.5 crore. 该公司以美国市场的特种药品为重点,将列入NSE和BSE清单。 The company, focused on specialty pharmaceuticals for the U.S. market, will list on the NSE and BSE. 灰色市场溢价为80,显示可能上市价为565。 The grey market premium stands at ₹80, indicating a potential listing price of ₹565. 公司主要经理包括:轴心资本,JM金融,SBI资本市场和IIFL资本,注册人为MUFG Intime India. Lead managers include Axis Capital, JM Financial, SBI Capital Markets, and IIFL Capital, with MUFG Intime India as registrar.